ATE435852T1 - Gpe-analoga und peptidomimetika - Google Patents

Gpe-analoga und peptidomimetika

Info

Publication number
ATE435852T1
ATE435852T1 AT02731918T AT02731918T ATE435852T1 AT E435852 T1 ATE435852 T1 AT E435852T1 AT 02731918 T AT02731918 T AT 02731918T AT 02731918 T AT02731918 T AT 02731918T AT E435852 T1 ATE435852 T1 AT E435852T1
Authority
AT
Austria
Prior art keywords
peptidomimetics
gpe
analogue
analogs
relates
Prior art date
Application number
AT02731918T
Other languages
English (en)
Inventor
Norman A Abood
Margaret Brimble
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE435852T1 publication Critical patent/ATE435852T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
AT02731918T 2001-05-24 2002-05-24 Gpe-analoga und peptidomimetika ATE435852T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29385301P 2001-05-24 2001-05-24
PCT/US2002/016361 WO2002094856A2 (en) 2001-05-24 2002-05-24 Gpe analogs and peptidomimetics

Publications (1)

Publication Number Publication Date
ATE435852T1 true ATE435852T1 (de) 2009-07-15

Family

ID=23130863

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731918T ATE435852T1 (de) 2001-05-24 2002-05-24 Gpe-analoga und peptidomimetika

Country Status (8)

Country Link
US (1) US7041314B2 (de)
EP (1) EP1401808B1 (de)
JP (1) JP2004536069A (de)
AT (1) ATE435852T1 (de)
AU (1) AU2002303856A1 (de)
DE (1) DE60232880D1 (de)
ES (1) ES2325983T3 (de)
WO (1) WO2002094856A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7863304B2 (en) * 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7485630B2 (en) * 2003-03-20 2009-02-03 Neuren Pharmaceuticals Limited Neuroprotective macrocyclic compounds and methods for their use
JP4972551B2 (ja) 2005-06-21 2012-07-11 興和株式会社 緑内障の予防又は治療剤
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
US7994127B2 (en) * 2007-06-08 2011-08-09 Massachusetts Institute Of Technology Treatment of rett syndrome
JP2009016396A (ja) * 2007-06-29 2009-01-22 Optical Comb Inc 波長走査型ファイバレーザ光源
EP2338492A1 (de) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Verfahren und Zusammensetzung zur Behandlung von Alzheimer
SI2667715T1 (sl) 2011-01-27 2017-11-30 Neuren Pharmaceuticals Limited Zdravljenje motenj avtističnega spektra z uporabo glicil-l-2-metilprolil-l-glutaminske kisline
EP2928300A4 (de) * 2012-11-28 2016-07-13 Neuren Pharmaceuticals Ltd Behandlung von autistischen erkrankungen mit glycyl-l-2-methylprolyl-l-glutaminsäure
CA2922239A1 (en) * 2013-09-23 2015-03-26 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Anti-inflammatory tripeptides
CN114667136A (zh) 2019-08-05 2022-06-24 诺仁制药有限公司 Trofinetide的组合物
US11827600B2 (en) 2021-07-12 2023-11-28 Acadia Pharmaceuticals Inc. Crystalline forms of trofinetide
CN120000765A (zh) * 2025-03-28 2025-05-16 首都医科大学宣武医院 一种gpe类似物在制备预防和/或治疗阿尔茨海默病的药物中的用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4699875A (en) 1982-11-24 1987-10-13 Baylor College Of Medicine Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
DK55685A (da) 1985-02-07 1986-08-08 Nordisk Gentofte Enzym eller enzymkompleks med proteolytisk aktivitet
US4511390A (en) 1983-06-10 1985-04-16 E. I. Du Pont De Nemours And Company Aralkylcarbamoyl peptide alcohols
US5149657A (en) 1984-09-13 1992-09-22 Enzon Labs Inc. Escherichia coli expression vector encoding bioadhesive precursor protein analogs comprising three to twenty repeats of the decapeptide (Ala-Lys-Pro-Ser-Tyr-Pro-Pro-Thr-Tyr-Lys)
DE3502041A1 (de) 1985-01-23 1986-07-24 Grünenthal GmbH, 5190 Stolberg Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden
US4783524A (en) 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
US5496712A (en) 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
JPH01501755A (ja) 1986-11-04 1989-06-22 シントロ　コーポレイション 合成ｄｎａの構成および大ポリペプチドの合成におけるその使用
US5243038A (en) 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5089406A (en) 1987-01-07 1992-02-18 Allied-Signal Inc. Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences
DE3851776T2 (de) 1987-04-28 1995-05-04 Boehringer Mannheim Gmbh Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
US4923696A (en) 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
WO1988009171A1 (en) 1987-05-19 1988-12-01 Baylor College Of Medicine Phosphoethanolamine for treatment of alzheimer's disease
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
JP2507106B2 (ja) 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
ATE86496T1 (de) 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
SE8803847A0 (sv) * 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
AU630643B2 (en) 1988-11-09 1992-11-05 Protein Polymers Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5114840A (en) 1989-07-07 1992-05-19 Karl Tryggvason Method for determining the nucleotide sequence of a novel α5(IV) chain of human type IV collagen
EP0816505B1 (de) 1990-11-28 2003-09-24 E.I. Du Pont De Nemours And Company Strukturproteine durch künstliche Gene
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5861373A (en) 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
DE69218948T2 (de) 1991-08-01 1997-07-31 Auckland Uniservices Ltd IGF-I zur Verbesserung der neuronale Lage
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5733871A (en) 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
WO1993010806A1 (en) 1991-11-25 1993-06-10 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
NZ253867A (en) 1992-06-12 1996-08-27 Cephalon Inc Treating peripheral neuropathy using igf-1 or igf-3
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
PT696205E (pt) 1993-04-13 2002-07-31 Us Gov Health & Human Serv Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
FR2707170A1 (fr) 1993-06-04 1995-01-13 Pasteur Institut Expression des récepteurs CD4 et CD26 dans des cellules recombinantes, inhibiteurs du récepteur CD26.
US5639729A (en) 1993-08-26 1997-06-17 Immunobiology Research Institute, Inc. Tripeptides useful in immune and CNS therapy
JPH09509140A (ja) 1993-11-15 1997-09-16 セルトリックス ファーマシューティカルズ，インコーポレイテッド 神経学的障害の治療方法
US5451660A (en) 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US6812208B2 (en) * 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
WO1995017204A1 (en) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
WO1995019567A1 (en) 1994-01-13 1995-07-20 The Trustees Of Columbia University In The City Of New York Synthetic receptors, libraries and uses thereof
US5710252A (en) 1995-02-03 1998-01-20 Eastman Kodak Company Method for recombinant yeast expression and isolation of water-soluble collagen-type polypeptides
US5670616A (en) 1995-02-03 1997-09-23 Eastman Kodak Company Collagen-like polypeptides and biopolymers and nucleic acids encoding same
US5965531A (en) 1995-08-31 1999-10-12 National Institutes Of Health Method of reducing perivascular lesions using insulin-like growth factor I
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
US5686423A (en) 1996-02-16 1997-11-11 Department Of Health, The Executive Yuan, Republic Of China Di-and tri-peptide mimetic compounds for Parkinson's disease
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
AU714318B2 (en) 1996-06-11 2000-01-06 Roche Diagnostics Gmbh Process for the activation of denatured protein
AU740783B2 (en) 1996-09-18 2001-11-15 Applied Genetics Incorporated Dermatics Pharmaceutical compositions and methods
WO1998014202A1 (en) 1996-10-04 1998-04-09 Auckland Uniservices Limited Regulation of neural enzymes
JP2001527451A (ja) 1997-05-16 2001-12-25 ノバルティス アクチエンゲゼルシャフト 細胞結合活性を有するコラーゲン様ポリマー
US6054579A (en) * 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
WO1999015192A1 (en) 1997-09-19 1999-04-01 Auckland Uniservices Limited Neuronal rescue agent
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
EP1087782A4 (de) 1998-06-15 2001-09-12 Neuronz Ltd Regulation der tyrosinhydroxylase
CN1261158C (zh) * 1998-09-03 2006-06-28 诺兰兹公司 生长激素在制备用于诱导神经保护作用的药剂中的应用
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
EP1043027A1 (de) 1999-04-08 2000-10-11 Applied Research Systems ARS Holding N.V. Behandlung von multiplersklerose mit einer kombination von interferon und Wachstumshormone
AU2001289160A1 (en) 2000-08-24 2002-03-04 Neuronz Ltd. Gpe analogs
AU2002246619A1 (en) 2000-12-08 2003-06-23 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US20020177239A1 (en) 2001-03-16 2002-11-28 Thomas Gregory Brian Anti-GPE antibodies, their uses, and analytical methods for GPE
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
WO2002088298A1 (en) * 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
EP2382982A3 (de) 2001-08-24 2012-02-22 Neuren Pharmaceuticals Limited Nervenregenerierungspeptid und Verfahren zu deren Verwendung bei der Behandlung einer Hirnschädigung

Also Published As

Publication number Publication date
ES2325983T3 (es) 2009-09-28
US7041314B2 (en) 2006-05-09
EP1401808A2 (de) 2004-03-31
US20030055004A1 (en) 2003-03-20
JP2004536069A (ja) 2004-12-02
DE60232880D1 (de) 2009-08-20
EP1401808A4 (de) 2004-08-25
EP1401808B1 (de) 2009-07-08
WO2002094856A2 (en) 2002-11-28
AU2002303856A1 (en) 2002-12-03
WO2002094856A3 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
DE60232880D1 (de) Gpe-analoga und peptidomimetika
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
NO20034230D0 (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
SE0301010D0 (sv) Novel compounds
SE0301009D0 (sv) Novel compounds
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
MXPA02006028A (es) Lipopeptidos novedosos como agentes antibacterianos.
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
ATE433447T1 (de) Pyrimiidinverbindungen
MEP90508A (en) New pharmaceutical composition
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
MXPA03010158A (es) Sulfonamidas.
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
EP1423137A4 (de) Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
UA86063C2 (ru) Липосомы для снабжения лекарств
GEP20247670B (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
NO20073762L (no) Visko-supplementsammensetning og fremgangsmater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties